News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Rare Disease Biopharma Rhythm Seeks $115 Million IPO



9/6/2017 7:22:27 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
A year after the team at Boston-based Rhythm Pharmaceuticals posted some compelling but limited Phase II data on its lead rare disease drug, the biotech is joining the queue to get onto Nasdaq with an IPO designed to raise around $115 million.

Already armed with the FDA’s breakthrough therapy title for setmelanotide, Rhythm is pitching the potential for its MC4R agonist for the treatment of rare genetic disorders of obesity — though Phase II included only two patients. And it’s out to sell investors on its rapid transition into Phase III studies for POMC deficiency obesity and LepR deficiency obesity while rolling out new Phase II trials to broaden its impact.

Read at News Release
Read at Nasdaq
Read at Renaissance Capital
Read at News Release


comments powered by Disqus
Rhythm
 
 
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES